Patents Examined by Daniel M. Sullivan
  • Patent number: 8389032
    Abstract: A delivery system for inclusion in an edible composition is formulated to have at least one active component with an encapsulating material for delivering the active component upon consumption of the edible composition.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: March 5, 2013
    Assignee: Kraft Foods Global Brands LLC
    Inventors: Navroz Boghani, Petros Gebreselassie
  • Patent number: 8263816
    Abstract: A process is disclosed for making CF3CF?CHF. The process involves reacting CF3CClFCCl2F with H2 in a reaction zone in the presence of a catalyst to produce a product mixture comprising CF3CF?CHF. The catalyst has a catalytically effective amount of palladium supported on a support selected from the group consisting of alumina, fluorided alumina, aluminum fluoride and mixtures thereof and the mole ratio of H2 to CF3CClFCCl2F fed to the reaction zone is between about 1:1 and about 5:1. Also disclosed are azeotropic compositions of CF3CClFCCl2F and HF and azeotropic composition of CF3CHFCH2F and HF.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: September 11, 2012
    Assignee: E I du Pont de Nemours and Company
    Inventors: Velliyur Nott Mallikarjuna Rao, Mario Joseph Nappa, Allen Capron Sievert
  • Patent number: 8101663
    Abstract: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: January 24, 2012
    Assignee: Merck HDAC Research, LLC
    Inventors: Thomas A. Miller, Victoria M. Richon
  • Patent number: 8063257
    Abstract: A method for preparing 2,3,3,3-tetrafluoropropene comprising contacting a reactant comprising CCl2?CFCH2Cl with a fluorinating agent, such as HF, under conditions effective to produce a reaction product comprising CF3CF?CH2.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: November 22, 2011
    Assignee: Honeywell International Inc.
    Inventors: Jing Ji Ma, Michael Van Der Puy
  • Patent number: 7989654
    Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: August 2, 2011
    Assignee: UCB Pharma GmbH
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Patent number: 7982071
    Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: July 19, 2011
    Assignee: Acucela Inc.
    Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
  • Patent number: 7977504
    Abstract: An object of the present invention is to provide a process for producing isocyanates, which are industrially useful compounds, without using phosgene, and to provide a process for chemically recycling waste polycarbonate resin. The present invention discloses a process enabling isocyanate compounds to be produced without using phosgene as a raw material by subjecting a carbamic acid ester compound obtained by a reaction between an aromatic polycarbonate resin and an amine compound to a thermal decomposition reaction, while at the same time disclosing a process enabling chemical recycling of aromatic polycarbonate resin by recovering a divalent aromatic hydroxy compound forming aromatic polycarbonates.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: July 12, 2011
    Assignee: Asahi Kasei Chemicals Corporation
    Inventors: Masaaki Shinohata, Nobuhisa Miyake
  • Patent number: 7968741
    Abstract: A method of preparing a disilanol compound by hydrolyzing a dichlorosilane compound having Si—Cl bonds at both ends, characterized in that the method comprises the step of hydrolyzing the dichlorosilane compound in the presence of a tertiary amine compound.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: June 28, 2011
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Yasunori Sakano, Takashi Matsuda, Noriyuki Koike
  • Patent number: 7968752
    Abstract: Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: June 28, 2011
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Ving Lee, Jacob J. Plattner, Stephen J. Benkovic, Stephen J. Baker, Kirk R. Maples, Carolyn Bellinger-Kawahara, Tsutomu Akama, Yong-Kang Zhang, Rajeshwar Singh, Vittorio A. Sauro
  • Patent number: 7960583
    Abstract: The invention encompasses processes for the synthesis of (S)-(+)-3-(aminomethyl) -5-methylhexanoic acid, (S)-Pregabalin, and intermediates of (S)-Pregabalin.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: June 14, 2011
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Vinod Kumar Kansal, Brijnath P. Chaurasia, V. Govardhan Rao, Anand Prakash Tiwari
  • Patent number: 7960578
    Abstract: The disclosure relates to a method for the synthesis of a compound of the formula (I) in which: n is an integer higher than or equal to 1; Rb and each Rn are independently a hydrogen atom, a C1-C6 arylalkyl group or a C1-C6 alkyl group substituted or not by an aryl group, —COOH, C1-C6, —COO-(alkyl), —CONH2, —SH, heteroaryl, —NH2, —NHC(NH)(NH2), C1-C6-s-(alkyl), —OH or phenol; Ra is a N-protective group; Rc is a ORd group in which Rd is a C1-C6 alkyl group or a NReRf group in which Re and Rf Re independently an N-protective group.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: June 14, 2011
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier I
    Inventors: Jean Martinez, Frédéric Lamaty, Valérie Declerck
  • Patent number: 7956218
    Abstract: The present invention relates to stable salts of ?-alanine and an organic acid endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: June 7, 2011
    Assignee: Northern Innovations and Formulations Corp.
    Inventors: Michele Molino, Joseph MacDougall
  • Patent number: 7951982
    Abstract: Disclosed is a process for the preparation of fluorinated olefins. In preferred embodiments C3 olefins are produced by methods comprising contacting a compound of the Formula (I) C(R1aR2bR3c)??(I) with a compound of Formula (II) C(R1aR2bR3c)Cn(R1aR2bR3c)??II wherein R1a, R2b, and R3c are independently a hydrogen atom or a halogen selected from the group consisting of fluorine; chlorine, bromine and iodine, provided that the compound of formula I has at least three halogen substituents and that said at three halogen substituents comprise at least one fluorine; a, b and c are independently=0, 1, 2 or 3 and (a+b+c)=2 or 3; and n is 0 or 1, under conditions effective to produce at least one C3 fluoroolefin.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: May 31, 2011
    Assignee: Honeywell International Inc.
    Inventors: Sudip Mukhopadhyay, Haridasan K. Nair, Hsueh S. Tung, Michael Van Der Puy, Robert C. Johnson, Daniel C. Merkel
  • Patent number: 7951971
    Abstract: Phenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: May 31, 2011
    Assignee: Emisphere Technologies, Inc.
    Inventors: Andrea Leone-Bay, Kelly Kraft, Destardi Moye-Sherman, David Gscheidner, Maria Aurora P. Boyd, Puchun Liu, Pingwah Tang, Jun Liao, John Smart, John J. Freeman, Jr.
  • Patent number: 7947738
    Abstract: It is intended to provide a bicyclic ?-amino acid derivative having excellent activity as an ?2? ligand. The present invention provides a compound represented by the general formula (I): wherein R1, R2, R2?, R4, R5, R6, R7, R8, and R8? are a hydrogen atom or the like; and R3 is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or the like.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: May 24, 2011
    Assignee: Daiichi Sankyo Company, Ltd.
    Inventors: Kousei Shimada, Asuka Kawamura, Naohisa Arakawa, Yuki Domon
  • Patent number: 7947851
    Abstract: The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of carboxylic acids of Formula (I) to modulate, notably to inhibit the activity of PTPs.
    Type: Grant
    Filed: March 29, 2005
    Date of Patent: May 24, 2011
    Assignee: Merck Serono SA
    Inventors: Dominique Swinnen, Catherine Jorand-Lebrun, Patrick Gerber, Jerome Gonzalez, Agnes Bombrun
  • Patent number: 7943797
    Abstract: The present invention consists on the synthesis of new products for the treatment of the iron chlorosis. These products may have improved properties regarding the currently known treatments. The new products are non-symmetrical ethylene diamino hydroxyphenyl acetic acid derivatives possessing only five coordination sites able to chelate metals.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: May 17, 2011
    Assignee: Tradecorp, S.A.
    Inventors: Miguel A. Sierra, Mar Gomez-Gallego, Juan J. Lucena, Sonia Garcia-Marco, Rosa Escudero
  • Patent number: 7939626
    Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).
    Type: Grant
    Filed: September 19, 2006
    Date of Patent: May 10, 2011
    Assignee: The Regents of the University of California
    Inventors: Eliana Saxon, Carolyn R. Bertozzi
  • Patent number: 7939568
    Abstract: The present invention is related to the use of a composition having an adequate pharmaceutical or cosmetic carrier or diluent and a sufficient amount of vitamin K1 oxide or its derivative for the treatment and/or the prevention of mammal dermatological lesions. The present invention is also related to a cosmetic composition having an adequate cosmetic carrier, phospholipids and vitamin K1 oxide or its derivative.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: May 10, 2011
    Assignee: Auriga International S.A.
    Inventor: Alfred Marchal
  • Patent number: 7935842
    Abstract: Three types of trisiloxane surfactants having the basic formula: MDM? are described wherein the substituents on the differing M and M? groups in conjunction with a pendant polyalkylene oxide substituents on the D group to render the surfactant resistant to hydrolysis under either basic or acidic conditions.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 3, 2011
    Assignee: Momentive Performance Materials Inc.
    Inventors: George A. Policello, Mark D. Leatherman, Wenqing Peng, Suresh K. Rajaraman, Zijun Xia